title: Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer.
abstract: Arzoxifene ([6-hydroxy-3-[4-[2-(1-piperidinyl)-ethoxy]phenoxy]-2-(4-methoxyphenyl)]benzo[b]thiophene) is a selective estrogen receptor modulator (SERM) that is a potent estrogen antagonist in mammary and uterine tissue while acting as an estrogen agonist to maintain bone density and lower serum cholesterol. Arzoxifene is a highly effective agent for prevention of mammary cancer induced in the rat by the carcinogen nitrosomethylurea and is significantly more potent than raloxifene in this regard. Arzoxifene is devoid of the uterotrophic effects of tamoxifen, suggesting that, in contrast to tamoxifen, it is unlikely that the clinical use of arzoxifene will increase the risk of developing endometrial carcinoma.
authors.affiliation: Department of Pharmacology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA.
authors.forename: N
authors.initials: N
authors.lastname: Suh
authors.forename: A L
authors.initials: AL
authors.lastname: Glasebrook
authors.forename: A D
authors.initials: AD
authors.lastname: Palkowitz
authors.forename: H U
authors.initials: HU
authors.lastname: Bryant
authors.forename: L L
authors.initials: LL
authors.lastname: Burris
authors.forename: J J
authors.initials: JJ
authors.lastname: Starling
authors.forename: H L
authors.initials: HL
authors.lastname: Pearce
authors.forename: C
authors.initials: C
authors.lastname: Williams
authors.forename: C
authors.initials: C
authors.lastname: Peer
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: M B
authors.initials: MB
authors.lastname: Sporn
mesh_terms: D000818:Animals; D016588:Anticarcinogenic Agents / Q000378:metabolism / Q000494:pharmacology*; D001667:Binding, Competitive; D002455:Cell Division / Q000187:drug effects; D004347:Drug Interactions; D004958:Estradiol / Q000494:pharmacology; D045166:Estradiol Congeners / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000378:metabolism / Q000494:pharmacology*; D004997:Ethinyl Estradiol / Q000494:pharmacology; D005260:Female; D006801:Humans; D008325:Mammary Neoplasms, Experimental / Q000473:pathology / Q000517:prevention & control*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology*; D051381:Rats; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors / Q000378:metabolism; D013629:Tamoxifen / Q000494:pharmacology; D013876:Thiophenes / Q000378:metabolism / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D014599:Uterus / Q000187:drug effects / Q000254:growth & development
chemical_list: D016588:Anticarcinogenic Agents; D045166:Estradiol Congeners; D004965:Estrogen Antagonists; D010880:Piperidines; D011960:Receptors, Estrogen; D013876:Thiophenes; D013629:Tamoxifen; D004997:Ethinyl Estradiol; D004958:Estradiol; C115121:LY 353381